Get the Stockscreener App
0.6027
4.79%
-0.0303
Pre-market:
.64
0.0373
+6.19%
Silexion Therapeutics Corp stock is traded at $0.6027, with a volume of 111.87K.
It is down -4.79% in the last 24 hours and down -50.19% over the past month.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
See More
Previous Close:
$0.633
Open:
$0.6313
24h Volume:
111.87K
Relative Volume:
1.88
Market Cap:
$2.46M
Revenue:
-
Net Income/Loss:
$-11.91M
P/E Ratio:
-0.068
EPS:
-8.8661
Net Cash Flow:
$-10.83M
1W Performance:
-5.38%
1M Performance:
-50.19%
6M Performance:
-79.84%
1Y Performance:
-96.06%
1-Day Range:
$0.59
$0.64
1-Week Range:
$0.5501
$0.67
52-Week Range:
$0.473
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.6027 | 2.46M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Silexion Therapeutics Shareholders Approve Capital Increase, Reverse Split - TipRanks
[8-K] Silexion Therapeutics Corp Reports Material Event - Stock Titan
SLXN (Silexion Therapeutics) posts wider than expected Q4 2025 loss, pushing shares 3.01 percent lower in today’s trading.Investor Call - Newser
SLXN (Silexion Therapeutics) posts wider than expected Q4 2025 loss, shares dip 0.94% in today’s trading. - Newser
Silexion Therapeutics Submits Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Pancreatic Cancer - Minichart
Silexion advances SIL204 to EU Phase 2/3 pancreatic trial - TipRanks
Silexion (NASDAQ: SLXN) advances SIL204 with German CTA step - Stock Titan
Pancreatic cancer drug SIL204 moves toward EU mid-stage trial - Stock Titan
Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN
What FIFO method Silexion Therapeutics (SLXN)? (Ticks Higher) 2026-04-27Hedge Fund Inspired Picks - Newser
Silexion stock jumps after toxicology studies show no systemic toxicity - MSN
Is Silexion Therapeutics (SLXN) stock undervalued compared to fundamentals | Q4 2025: Profit DisappointsTrending Buy Opportunities - Xã Thanh Hà
SLXN (Silexion Therapeutics Corp Ordinary Shares) rises seven percent even as Q4 2025 EPS falls short of analyst expectations.Trader Community Insights - Cổng thông tin điện tử tỉnh Tây Ninh
SLXN (Silexion Therapeutics Corp Ordinary Shares) misses Q4 2025 EPS estimates, shares drop 1.92% on cautious investor sentiment.Shared Momentum Picks - UBND thành phố Hải Phòng
SLXNW SEC FilingsSilexion Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
SLXN Stock Price, Quote & Chart | SILEXION THERAPEUTICS CORP (NASDAQ:SLXN) - ChartMill
Silexion (SLXN) plans big share boost, richer equity pool and reverse split - Stock Titan
Aug Chart Watch: Whats the profit margin of Silexion Therapeutics Corp2026 Geopolitical Influence & Safe Entry Point Alerts - baoquankhu1.vn
Institution Moves: Is Silexion Therapeutics Corp a strong growth stock2026 Selloffs & Weekly Market Pulse Updates - baoquankhu1.vn
Are short sellers targeting Silexion (SLXNW) Stock | Price at $0.01, Up 7.14%Fundamentals - Newser
CEO Moves: What is the PEG ratio of Silexion Therapeutics Corp Equity Warrant2026 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Fed Watch: Does GLBS stock have upside surprise potential2026 Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Can Silexion Therapeutics Corp stock beat analyst upgradesMarket Growth Report & AI Driven Stock Price Forecasts - Bollywood Helpline
ETF Watch: Can Silexion Therapeutics Corp Equity Warrant expand its profit margins - baoquankhu1.vn
Is Silexion Therapeutics (SLXN) Stock Showing Strength | Price at $1.17, Down 2.51%Crowd Trend Signals - Newser
SLXNW Stock Analysis: Silexion Therapeutics Corp Warrant Falls 31% to $0.01 Level - UBND thành phố Hải Phòng
EBIT per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView — Track All Markets
Hedge Fund Bets: Will Silexion Therapeutics Corp Equity Warrant benefit from government policy2026 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Market Recap: Whats the profit margin of Silexion Therapeutics Corp2026 Historical Comparison & Technical Entry and Exit Alerts - baoquankhu1.vn
Shorts Report: Whats the beta of Silexion Therapeutics Corp Equity Warrant stock2026 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Top Silexion Executive Quietly Unloads a Chunk of Company Stock - TipRanks
Silexion Therapeutics (SLXN) CSO logs sale-to-cover share transaction - Stock Titan
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors - MSN
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Trial of SIL204 in Locally Advanced Pancreatic Cancer - geneonline.com
Investor Mood: Can Silexion Therapeutics Corp be recession proofWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Silexion Therapeutics Announces Immediate Board Membership Change - tipranks.com
Ilan Levin removed from Silexion Therapeutics board - TradingView
Board at Silexion Therapeutics (NASDAQ: SLXN) removes Ilan Levin - Stock Titan
Is Silexion Therapeutics Corp a strong growth stockMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204 - TipRanks
Silexion Shareholders Reject Capital Increase and Plan Amendments - The Globe and Mail
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Clinical Trial of SIL204 in Advanced Pancreatic Cancer - minichart.com.sg
Silexion gets Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):